Tendyne Transcatheter Mitral Valve System
ABBOTT MEDICAL · Decision date Oct 4, 2025
What did the FDA approve?
FDA records P240042/S002 as a supplement to PMA P240042, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Oct 4, 2025.
FDA approval order statement
Approval of the protocol for the post-approval study, "Registry-Based Real-World Use Surveillance," submitted to comply with the conditions of approval outlined in the approval order for P240042.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 4, 2025
- FDA change category
- Postapproval Study Protocol
Regulatory record facts
- Identifier
- P240042/S002
- Regulatory pathway
- PMA supplement
- Applicant
- ABBOTT MEDICAL
- Product code
- NPU
- Decision code
- APPR
- Decision date
- Oct 4, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Prosthesis, mitral valve, percutaneously delivered.
- Applicant
- Abbott Medical
- Product code
- NPU
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P240042/S001 · Related supplement
Tendyne Transcatheter Mitral Valve
P240042/S002 received
Application receipt date recorded by FDA.
P240042/S002 · FDA decision
Normal 180 Day Track No User Fee
P240042/S003 · Related supplement
Tendyne Transcatheter Mitral Valve System
P240042/S004 · Related supplement
Tendyne Transcatheter Mitral Valve System
Timeline entries are records held by MedtechLedger for P240042. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240042
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Tendyne Transcatheter Mitral ValveP240042/S001 | ABBOTT MEDICAL | PMA supplement | Jul 29, 2025 | FDA |
Tendyne Transcatheter Mitral Valve SystemP240042/S003 | ABBOTT MEDICAL | PMA supplement | Aug 7, 2026 | FDA |
Tendyne Transcatheter Mitral Valve SystemP240042/S004 | ABBOTT MEDICAL | PMA supplement | Aug 31, 2026 | FDA |
Explore the linked device profile
Other records with product code NPU
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Edwards Lifesciences, LLC | PMA supplement | Jul 29, 2026 | FDA | |
SAPIEN M3 Transcatheter Heart Valve (9880TFX29M)P250019/S005 | Edwards Lifesciences, LLC | PMA supplement | Jul 28, 2026 | FDA |
| Edwards Lifesciences, LLC | PMA supplement | Apr 16, 2026 | FDA | |
| Edwards Lifesciences, LLC | PMA supplement | Mar 11, 2026 | FDA | |
| Edwards Lifesciences, LLC | PMA supplement | Feb 19, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Abbott Medical
- Headquarters
- Not reported
- Brand website
- abbott.com
- FDA applicant address
- 177 County Rd. B E., St. Paul, MN, 55117
Sources and methodology
- Original FDA record: P240042/S002
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
